Registration is now open for the Colorado BioScience Association (CBSA) Annual Awards Dinner, featuring Keynote Presenter Rick Guidotti, world renowned photographer and co-founder of New York-based Positive Exposure. The CBSA awards event is Thursday, December 8, at the Embassy Suites in Downtown Denver.  

Gilead and GlobeImmune Announce License and Collaboration Agreement to Develop Therapeutic Vaccine Products for Treatment of Chronic Hepatitis B Infection 

Boulder, CO, October 24, 2011 – MBio Diagnostics, Inc. today announced publication of study results in the American Society for Microbiology’s Journal of Clinical Microbiology (Lochhead, MJ, et al, J. Clin. Micro. 2011, 49, 3584-3590). MBio is developing a point-of-care diagnostic system that delivers a panel of infectious disease results using a single drop of blood. The peer-reviewed article is titled “Rapid Multiplexed Immunoassay for Simultaneous Serodiagnosis of HIV-1 and Coinfections.” It was authored by a team of scientists from the company and physicians at the University of California, San Diego (UCSD). 

Denver Business Journal by Greg Avery, Reporter  

Contact:
Laura Fusco
Global Corporate Communications
Phone: +1 303.205.2546
press@caridianbct.com 

Riebel was nominated in the Technology & Telecommunications Division. Quoting from the DBJ website: "The Colorado BioScience Association has managed to keep the state’s biotech drug and medical-device industries in the minds of public policy makers and national investors at a time of tight funding. CEO and President Holli Riebel (formerly Holli Baumunk) has maintained support for the industry during her first year leading the organization. CBSA organizes a regional conference that each year attracts investors from biotech hubs on the East and West Coasts, and it’s worked to keep state tax incentives and other support largely intact at a time when state funding has been cut for many other programs."

Learn more at the DBJ website. 

Northern Colorado Business Report  

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today that the Agreement and Plan of Merger and Reorganization ("the Merger Agreement") entered into by and among Allos, AMAG and Alamo Acquisition Sub, Inc. on July 19, 2011, as amended on August 8, 2011, has been terminated. The Merger Agreement was terminated following the October 21, 2011, special meeting of AMAG stockholders at which AMAG's stockholders voted against the issuance of shares of AMAG common stock to Allos' stockholders in the proposed merger. Separately, a majority of Allos' stockholders voted in favor of the adoption of the Merger Agreement at a special meeting of Allos stockholders also held on October 21, 2011.

"The Board and shareholders of Allos supported the proposed merger with AMAG based on the strategic rationale, anticipated operating synergies and potential for future growth of the core brands. With the termination of the merger agreement, we will remain focused on growing U.S. sales of FOLOTYN for relapsed or refractory PTCL, as well as pursuing future label expansion opportunities in T-cell lymphoma and regulatory approval in the EU, which may occur in early 2012," commented Paul L. Berns, President and Chief Executive Officer of Allos. "We ended the third quarter with no debt and $100.4 million in cash and investments, which based on our historical sales levels for the first nine months of 2011, we believe will be sufficient to fund our operations through early 2014. Achievement of growth in U.S. sales and/or potential milestone payments and royalties associated with regulatory approval of FOLOTYN in the EU would further extend our cash resources."

About Allos Therapeutics

Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. Allos is currently focused on the development and commercialization of FOLOTYN® (pralatrexate injection), a folate analogue metabolic inhibitor. FOLOTYN is approved in the U.S. for the treatment of patients with relapsed or refractory PTCL. For additional information, please visit www.allos.com.

 

Golden, CO – October 21, 2011 – PharmaJet has received two FDA 510(k) marketing clearances for its IM/SC injection technology. Below are the INDICATIONS FOR USE, cleared by the FDA.